15 results match your criteria: "John Vane Science Center[Affiliation]"
Pharmacol Rep
June 2023
Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.
Pharmacol Rep
June 2023
Center for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI)-a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, EC1M 6BQ, UK.
Background: Pegylated arginine deiminase (ADI-PEG20; pegargiminase) depletes arginine and improves survival outcomes for patients with argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM). Optimisation of ADI-PEG20-based therapy will require a deeper understanding of resistance mechanisms, including those mediated by the tumor microenvironment. Here, we sought to reverse translate increased tumoral macrophage infiltration in patients with ASS1-deficient MPM relapsing on pegargiminase therapy.
View Article and Find Full Text PDFJ Exp Med
January 2023
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem.
View Article and Find Full Text PDFCancer Res
May 2022
Barts Cancer Institute-A CR-UK Center of Excellence, Queen Mary University of London, John Vane Science Center, Charterhouse Square, London, United Kingdom.
Unlabelled: Despite substantial advances in the treatment of solid cancers, resistance to therapy remains a major obstacle to prolonged progression-free survival. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a high level of liver metastasis. Primary PDAC is highly hypoxic, and metastases are resistant to first-line treatment, including gemcitabine.
View Article and Find Full Text PDFCancer Med
October 2021
Department of Histopathology, Pathology and Pharmacy Building, Barts Health NHS Trust, Royal London Hospital, London, UK.
Introduction: We evaluated the arginine-depleting enzyme pegargiminase (ADI-PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1-deficient non-squamous non-small cell lung cancer (NSCLC) via a phase 1 dose-expansion trial with exploratory biomarker analysis.
Methods: Sixty-seven chemonaïve patients with advanced non-squamous NSCLC were screened, enrolling 21 ASS1-deficient subjects from March 2015 to July 2017 onto weekly pegargiminase (36 mg/m ) with Pem (500 mg/m ) and Cis (75 mg/m ), every 3 weeks (four cycles maximum), with maintenance Pem or pegargiminase. Safety, pharmacodynamics, immunogenicity, and efficacy were determined; molecular biomarkers were annotated by next-generation sequencing and PD-L1 immunohistochemistry.
Cancer Res
June 2020
European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
The angiopoietin (Angpt)-TIE signaling pathway controls vascular maturation and maintains the quiescent phenotype of resting vasculature. The contextual agonistic and antagonistic Tie2 ligand ANGPT2 is believed to be exclusively produced by endothelial cells, disrupting constitutive ANGPT1-TIE2 signaling to destabilize the microvasculature during pathologic disorders like inflammation and cancer. However, scattered reports have also portrayed tumor cells as a source of ANGPT2.
View Article and Find Full Text PDFOncogenesis
November 2019
Department of Experimental Medicine, Sapienza University, 00161, Rome, Italy.
Medulloblastoma (MB) is the most common malignant childhood brain tumor. About 30% of all MBs belong to the I molecular subgroup, characterized by constitutive activation of the Sonic Hedgehog (Hh) pathway. The Hh pathway is involved in several fundamental processes during embryogenesis and in adult life and its deregulation may lead to cerebellar tumorigenesis.
View Article and Find Full Text PDFOncotarget
November 2017
Peter W. Szlosarek: Center for Molecular Oncology, Barts Cancer Institute - a Cancer Research UK Center of Excellence, Queen Mary University of London, John Vane Science Center, London, UK and Barts Health NHS Trust, St Bartholomew's Hospital, London, UK.
JAMA Oncol
January 2017
Cancer Research UK and UCL Cancer Trials Center, University College London, London, England.
Importance: Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been evaluated in a randomized and biomarker-driven study among patients with cancer.
Objective: To assess the clinical impact of arginine depletion in patients with ASS1-deficient malignant pleural mesothelioma.
Cell Adh Migr
May 2017
a Centre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, Barts and The London, School of Medicine and Dentistry , Queen Mary University of London, Whitechapel, London , UK.
E-cadherin mediated cell-cell adhesion plays a critical role in epithelial cell polarization and morphogenesis. Our recent studies suggest that the desmosomal cadherin, desmoglein 3 (Dsg3) cross talks with E-cadherin and regulates its adhesive function in differentiating keratinocytes. However, the underlying mechanism remains not fully elucidated.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2014
Barts Cancer Institute, Queen Mary University of London, Center for Molecular Oncology, John Vane Science Center, London EC1M 6BQ, United Kingdom
Cancer Res
February 2014
Authors' Affiliations: Barts Cancer Institute-a Cancer Research UK Center of Excellence, John Vane Science Center, Queen Mary University of London; Department of Medicine, Imperial College, Charing Cross Campus; St Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London; Wellcome Trust Center for Human Genetics, Oxford; Cancer Research UK Cambridge Research Institute, Li Ka Shing Center; Hutchison/MRC Research Center, University of Cambridge, Medical Research Council Cancer Unit; Pharmacometrics Ltd., Cambridge; Dundee Cancer Center, University of Dundee, Ninewells Hospital, Dundee, United Kingdom; Laboratory of Cancer Genetics and Translational Oncology, S Croce General Hospital, Cuneo, Italy; Department of Structural Biology, Medical University of Lodz, Lodz, Poland; Polaris Group, San Diego, California; Department of Pathology, Chi-Mei Medical Center; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan; and National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Targeted therapies have yet to have significant impact on the survival of patients with bladder cancer. In this study, we focused on the urea cycle enzyme argininosuccinate synthetase 1 (ASS1) as a therapeutic target in bladder cancer, based on our discovery of the prognostic and functional import of ASS1 in this setting. ASS1 expression status in bladder tumors from 183 Caucasian and 295 Asian patients was analyzed, along with its hypothesized prognostic impact and association with clinicopathologic features, including tumor size and invasion.
View Article and Find Full Text PDFCell Death Differ
March 2010
Cell Survival Signalling Laboratory, Center for Molecular Oncology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, John Vane Science Center, Charterhouse Square, London, UK.
J Biosci
December 2004
Queen Mary Intellectual Property Research Institute, John Vane Science Center, Charterhouse Square, London EC1M 6BQ, UK.
This article assesses the traditional systems of accessing and using plant genetic resources as well as the benefit sharing and systems of sanctioning infringement in the context of biodiversity related activities in specific areas in the Northwest province of Cameroon. The article also addresses the type research and development activities using plant genetic resources and associated traditional knowledge in the context of Cameroon, the current laws regulating such activities and the extent to which these activities and laws affect and/or protect the customary biodiversity rights of rural communities. The article uses these assessments to suggest the context under which a sui generis legislation for the protection of the biodiversity rights of rural communities can be established in Cameroon.
View Article and Find Full Text PDFMethods Mol Biol
July 2003
ICRF Medical Oncology Unit, John Vane Science Center, Queen Mary and Westfield College, London, UK.